Table 1 Demographic and clinical characteristics of participants according to the presence of AF
| Â | AF (204) | Non-AF (708) | P |
|---|---|---|---|
Age (years) | 68.78 ± 11.15 | 56.25 ± 10.31 |  < 0.001 |
Gender (male) | 132 (64.7) | 429 (60.6) | 0.287 |
Smoke [(n%)] | 76 (37.3) | 305 (43.1) | 0.137 |
HT [(n%)] | 149 (73.0) | 382 (54.0) |  < 0.001 |
DM [(n%)] | 64 (31.4) | 201 (28.4) | 0.408 |
CHD [(n%)] | 121 (59.3) | 352 (49.7) | 0.016 |
BMI (kg/m2) | 26.47 ± 2.95 | 25.89 ± 2.75 | 0.013 |
SBP (mmHg) | 136.36 ± 20.15 | 130.84 ± 18.27 |  < 0.001 |
DBP (mmHg) | 80.09 ± 14.14 | 79.99 ± 12.76 | 0.934 |
ALT (U/L) | 23.20 (17.25,29.18) | 24.35 (16.83,33.00) | 0.197 |
AST (U/L) | 22.30 (18.50,27.60) | 22.70 (18.20,28.80) | 0.540 |
Scr (mmol/L) | 71.00 (63.00,82.00) | 66.00 (56.00,75.00) |  < 0.001 |
TC (mmol/L) | 3.71 (3.10,4.50) | 4.43 (3.66,5.23) |  < 0.001 |
TG (mmol/L) | 1.81 (1.27,2.39) | 1.60 (1.24,2.09) | 0.008 |
HDL-C (mmol/L) | 1.02 (0.90,1.19) | 1.10 (0.94,1.29) |  < 0.001 |
LDL-C (mmol/L) | 2.02 (1.49,2.57) | 2.38 (1.91,2.87) |  < 0.001 |
FBG (mmol/L) | 5.89 (5.24,7.65) | 5.50 (4.89,6.47) |  < 0.001 |
Anti-diabetic drugs[(n%)] | 55 (27.0) | 181 (25.6) | 0.688 |
Lipid-lowering drugs[(n%)] | 73 (35.8) | 205 (29.1) | 0.062 |
TyG | 9.12 ± 0.53 | 8.01 ± 0.44 |  < 0.001 |